Clinical TrialMay 21, 2026, 05:11 PM
Autolus obe-cel shows 59% ORR, 42.6-month mDOR in B-ALL EMD
AI Summary
Autolus Therapeutics announced the online publication of an abstract for the American Society of Clinical Oncology (ASCO) Annual Meeting, detailing positive data for its programmed T cell therapy, obe-cel. A post-hoc analysis of the Phase Ib/II FELIX study showed that obe-cel demonstrated an overall response rate of 59% and a median duration of response of 42.6 months in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD). These findings suggest obe-cel as a potential treatment option for this difficult-to-treat patient population.
Key Highlights
- Obe-cel achieved an overall response rate of 59% in B-ALL patients with extramedullary disease (EMD).
- Median duration of response (mDOR) for EMD patients was 42.6 months.
- 27 out of 127 (21%) obe-cel infused patients had EMD at lymphodepletion.
- The data suggests a positive benefit-risk profile for obe-cel, including for patients with EMD.
- Results from the Phase Ib/II FELIX study will be presented at ASCO 2026.
Price Impact
More from AUTL